NasdaqGS:MYGN

Stock Analysis Report

Executive Summary

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.

Risks

  • Myriad Genetics has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Myriad Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-44.6%

NasdaqGS:MYGN

1.5%

US Biotechs

0.9%

US Market


1 Year Return

-40.2%

NasdaqGS:MYGN

-7.3%

US Biotechs

0.3%

US Market

MYGN underperformed the Biotechs industry which returned -8% over the past year.

MYGN underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

MYGNIndustryMarket
7 Day-44.6%1.5%0.9%
30 Day-12.0%2.2%-1.9%
90 Day-2.6%3.5%1.6%
1 Year-40.2%-40.2%-6.5%-7.3%2.6%0.3%
3 Year18.7%18.7%8.9%5.2%41.0%31.8%
5 Year-31.3%-31.3%6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myriad Genetics undervalued based on future cash flows and its price relative to the stock market?

11%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Myriad Genetics's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Myriad Genetics's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Myriad Genetics is overvalued based on earnings compared to the US Biotechs industry average.

Myriad Genetics is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Myriad Genetics is poor value based on expected growth next year.


Price Based on Value of Assets

Myriad Genetics is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Myriad Genetics expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

80.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Myriad Genetics's revenue is expected to grow by 3.2% yearly, however this is not considered high growth (20% yearly).

Myriad Genetics's earnings are expected to grow significantly at over 20% yearly.

Myriad Genetics's revenue growth is positive but not above the United States of America market average.

Myriad Genetics's earnings growth is expected to exceed the United States of America market average.

Myriad Genetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Myriad Genetics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Myriad Genetics performed over the past 5 years?

-20.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Myriad Genetics's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Myriad Genetics's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Myriad Genetics's 1-year earnings growth is negative, it can't be compared to the US Biotechs industry average.


Return on Equity

Myriad Genetics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Myriad Genetics used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Myriad Genetics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Myriad Genetics's financial position?


Financial Position Analysis

Myriad Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Myriad Genetics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Myriad Genetics's level of debt (21.4%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Myriad Genetics's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (35.8%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 3.4x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.5x debt.


Next Steps

Dividend

What is Myriad Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Myriad Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Myriad Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Myriad Genetics has not reported any payouts.

Unable to verify if Myriad Genetics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Myriad Genetics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Myriad Genetics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Myriad Genetics's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Mark Capone (57yo)

4.1yrs

Tenure

US$7,054,950

Compensation

Mr. Mark Christopher Capone has been the Chief Executive Officer and President at Myriad Genetics Inc. since July 1, 2015. Mr. Capone served as the President of Myriad Genetic Laboratories at Myriad Geneti ...


CEO Compensation Analysis

Mark's remuneration is higher than average for companies of similar size in United States of America.

Mark's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

4.1yrs

Average Tenure

54.5yo

Average Age

The tenure for the Myriad Genetics management team is about average.


Board Age and Tenure

9.9yrs

Average Tenure

67yo

Average Age

The tenure for the Myriad Genetics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$61,22512 Mar 19
Ralph McDade
EntityIndividual
Shares1,975
Max PriceUS$31.00

Ownership Breakdown


Management Team

  • Gary King (63yo)

    Executive Vice President of International Operations

    • Tenure: 9.1yrs
  • Jerry Lanchbury (60yo)

    Chief Scientific Officer

    • Tenure: 9.5yrs
    • Compensation: US$2.38m
  • Rishi Kacker

    Chief Technology Officer

    • Tenure: 1.1yrs
  • Scott Gleason

    Vice President of Investor Relations

    • Tenure: 0.0yrs
  • Mark Capone (57yo)

    CEO, President & Director

    • Tenure: 4.1yrs
    • Compensation: US$7.05m
  • Ron Rogers (51yo)

    Executive Vice President of Corporate Communications

    • Tenure: 0.0yrs
  • R. Riggsbee (48yo)

    Executive VP

    • Tenure: 4.8yrs
    • Compensation: US$2.65m
  • Alec Ford (52yo)

    President of Myriad Women’s Health

    • Tenure: 4.1yrs
    • Compensation: US$2.76m
  • Ben Jackson

    Executive VP

    • Tenure: 0.1yrs
  • Clivetty Martinez

    Chief Compliance Officer

    • Tenure: 0.6yrs

Board Members

  • Larry Best (70yo)

    Director

    • Tenure: 9.9yrs
    • Compensation: US$330.49k
  • Wally Gilbert (87yo)

    Vice Chairman

    • Tenure: 0.0yrs
    • Compensation: US$319.99k
  • John Henderson (75yo)

    Chairman

    • Tenure: 14.3yrs
    • Compensation: US$432.49k
  • Dennis Langer (67yo)

    Director

    • Tenure: 15.3yrs
    • Compensation: US$340.49k
  • Heiner Dreismann (66yo)

    Director

    • Tenure: 9.2yrs
    • Compensation: US$334.99k
  • Mark Capone (57yo)

    CEO, President & Director

    • Tenure: 4.1yrs
    • Compensation: US$7.05m
  • S. Phanstiel (61yo)

    Director

    • Tenure: 9.9yrs
    • Compensation: US$347.49k

Company Information

Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Myriad Genetics, Inc.
  • Ticker: MYGN
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.853b
  • Shares outstanding: 73.87m
  • Website: https://myriad.com

Number of Employees


Location

  • Myriad Genetics, Inc.
  • 320 Wakara Way
  • Salt Lake City
  • Utah
  • 84108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1995
MYDDB (Deutsche Boerse AG)YesCommon StockDEEUROct 1995
0K3WLSE (London Stock Exchange)YesCommon StockGBUSDOct 1995

Biography

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 23:40
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.